FOR IMMEDIATE RELEASE
Tuesday, October 6, 1998
NCI Press Office
With Herceptin® Now Available, Registration Ends for NCI's Expanded Access Program
- Last spring, NCI and Genentech arranged to make the drug available in more locations. Through its Treatment Referral Center, NCI opened a new expanded access protocol, known as TRC-9801. Eligible patients, selected through the lottery, could enroll in this study at any NCI-designated cancer center that had approved the TRC-9801 protocol.
- The lottery ended on Sept. 18. With supplies of the drug increasing, TRC-9801 was opened to any eligible patient who had been entered on the lottery but not selected, as well as other eligible patients.
- At the same time, NCI initiated a second protocol, called TP-98-01, for those who entered the lottery but were not selected. TP-98-01 allows patients to participate in the expanded access protocol with their local oncologists rather than by traveling to a participating cancer center.
In addition to the reimbursement hotline given above, Genentech has two other information lines: Genentech Medical Information (1-800-448-3405) provides medical and full prescribing information to health care professionals and consumers. In addition, Genentech Customer Service (1-800-551-2231) provides ordering and shipping information.
More information on NCI's expanded access protocols is available from the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237)
For more information about cancer, visit NCI's Web site for patients, public and the mass media at http://rex.nci.nih.gov or NCI's main web site at http://www.nci.nih.gov.